Tag: IDH1 mutant glioma treatment

Home / IDH1 mutant glioma treatment

Categories

The FDA has granted approval for the use of vorasidenib in the treatment of Grade 2 astrocytoma or oligodendroglioma in patients having a specific IDH1 or IDH2 mutation

August 2024: Vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), has been approved by the Food and Drug Admini...
idh1-mutant-glioma-treatment